natgillin/translations-raw huggingface dataset:
A pharmaceutical composition according to claim 5 comprising a crystalline form of a compound of Formula XI 2-(2-fluoro-4-iodphenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide substantially in the form of Form 2 characterized by an X-ray diffraction pattern having characterizing peaks at about 9.5 and 12.6 on the 2θ scale, in combination with an anti-tumor agent or a signal transduction inhibitor. 
Kristalni oblik spoja formule XI [image] bitno u obliku oblika 2, 2-(2-fluoro-4-jodofenilamino)-N-(2-hidroksietoksi)-1,5-dimetil-6-okso-1,6-dihidropiridin-3-karboksamid naznačen time da uzorkom rendgenske difrakcije koja ima karakterizirajuće šiljke na oko 9.5 i 12.6 na skali 2θ.
The base TPE may also be selected on the basis of properties known to be suitable for use as vial closures and plungers, e.g. elasticity, hardness, compatibility with pharmaceutical uses etc. 
Osnovni TPE može također biti odabran na temelju poznatih svojstava, koja svojstva su prikladna za upotrebu kod zatvarača bočica i kod klipova, na primjer, kao što su elastičnost, tvrdoća, kompatibilnost s farmaceutskom upotrebom i tako dalje.
The redox flow battery of claim 1, wherein the flow path frame is provided on a surface thereof with an inflow path conveying the electrolyte being introduced through the common flow path, and on an opposite surface with an outflow path conveying the electrolyte received from the inflow path to the impregnation part. 
Baterija s redoks protokom u skladu s patentnim zahtjevom 1, naznačena time, da okvir za putanju protoka (120, 210) ima na svojoj površini dovodnu putanju (115, 112) koja prenosi elektrolit koji se unosi kroz zajedničku protočnu putanju i na suprotnoj površini odvodnu putanju (113, 114) koja prenosi elektrolit iz dovodne putanje do dijela za impregnaciju.
In an embodiment, the immunogenic composition of the invention comprises at least one, two, three or four N. meningitidis bacterial saccharide(s) conjugated to a carrier protein selected from the group consisting of TT, DT, CRM197, fragment C of TT and protein D. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje dva dodatna bakterijska saharida su konjugirani s proteinskim nosačem kojeg se bira iz skupine koju čine TT, DT, CRM197, C fragment proteina TT, protein D, OMPC i pneumolizin.
extracting the aqueous composition with an organic solvent followed by isolation of the aqueous layer, wherein the aqueous composition of step (b) or (c) comprises the aqueous layer isolated from step (a). 
(a) ekstrahiranje vodene smjese organskim otapalom nakon čega slijedi izoliranje vodenog sloja, gdje vodena smjesa iz koraka (b) ili (c) sadrži vodeni sloj izoliran iz koraka (a).
YisF,HorCl; and R2 are independently H, C1 - C4 alkyl or CH2CH2OH; or R1 and R2 together with the nitrogen atom to which they are attached form a pyrrolidine ring optionally substituted with hydroxymethyl at the 2-position or hydroxy at the 3-position, or an azetidine ring substituted with hydroxy at the 3-position; 
R' i R? su neovisno H, C;-Ca alkil ili CH;CH2OH,; ili Ri R?, zajedno s atomom dušika na kojeg su vezani, tvore pirolidinski prsten, izborno supstituiran s hidroksimetilom na položaju 2 ili s hidroksi na položaju 3, ili azetidinski prsten, supstituiran s hidroksi na položaju 3;
The microcapsule composition according to claim 2, having a sustained release for a period of 8 days from the administration of said microcapsule composition. 
Oblik mikrokapsule prema zahtjevu 2, koja ima produljeno oslobađanje za period od 8 dana od primjene te mikrokapsule.
Sugar replacement composition, according to a fifth specific embodiment of the invention. 
Sastavina koja zamjenjuje šećer, prema petoj specifičnoj varijanti Minimalna relativna Maksimalna relativna
Example 8: Effects on Learning 
Primjer 9: Učinak na učenje
Thus, using the general approach described herein is it possible to prepare a wide range of rapamycin carbohydrate derivatives in which the 31- and/or 42-hydroxyl groups are modified with a wide range of sugars or sugar derivatives. 
Prema tome, upotrebom općenitog pristupa, kakav je ovdje opisan, moguće je pripremiti širok raspon ugljikohidratnih derivata rapamicina u kojima su 31- i/ili 42-hidroksilne grupe modificirane širokim rasponom šećera ili šećernih derivata.
The method of claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is provided as a single agent or in combination with another pharmaceutical agent in a patient with a newly diagnosed hematologic malignant neoplastic disorder, to maintain remission, or a relapsed/refractory hematologic malignant neoplastic disorder patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli daje subjektu s novodijagnosticiranom akutnom mijeloičnom Ieukemijom (AML), da bi se održala remisija ili subjektu s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
A pharmaceutical composition comprising cortexolone-17a-propionate in crystalline form I according to claim 12 or 13 and at least one physiologically acceptable excipient. The pharmaceutical composition according to claim 14 in solid, semi-solid, pasty or liquid form. 
Farmaceutski pripravak koji sadrži korteksolon-17a-propionat u kristalnom obliku III u skladu s bilo kojim od patentnih zahtjeva 15 do 18, naznačen time što je navedeni spoj u smjesi s najmanje jednom fiziološki prihvatljivom pomoćnom tvari.
Plant according to claim 4 further comprising an oil separator (32) downstream said first collection tank and upstream said primary treatment unit. 
Postrojenje u skladu s patentnim zahtjevom 4, naznačeno time što dodatno sadrži odvajač ulja (32), nizvodno od navedenog prvog sabirnog spremnika, a uzvodno od navedene jedinice za primarnu obradu.
● R5 and R6 are, each independently, C1-6alkyl; or together with the two oxygen atoms to which they are attached to, form a 4-7 membered heterocyclic ring optionally substituted with one substituent selected from halo, C1-6alkyl, C2-6alkenyl, haloC1-6alkyl, trimethylsilyl, trimethylsilylmethyl, phenyl, 2-nitrophenyl, 4-methoxyphenyl, 2-pyridyl; or the 4-7 membered heterocyclic ring is optionally substituted with two substituents selected from halo and C1-6alkyl. 
RiR su, svaki neovisno, Cisalkil, polihalogenC, salkil, -C(=0)-C, salkil, fenil, benzil, izborno supstituiran s nitro; ili, zajedno s dva atoma kisika na koje su vezani, tvore 4-7-eročlani heterociklički prsten, izborno supstituiran s jednim supstituentom, kojeg se bira između halogena, Cisalkila, C2galkenila, polihalogenC; salkila, triC,. calkilsilila, diC, galkilfenilsilila, C, galkildifenilsilila, triC; galkilsikIC, galkila, diC, galkilfenilsiiIC, galkila, C,.
The system of claim 1, wherein the system is operable over a communications network. A method to permit a communication of at least one set of controlled credentials connected to a presenter from at least one server to a network endpoint, said method comprising the following steps performed by at least one server: 
Postupak koji omogućuje slanje najmanje jednog kompleta kontroliranih vjerodajnica povezano s prikazivačem iz najmanje jednog servera u krajnju točku mreže (110), naznačen time što se navedeni postupak sastoji u sljedećim koracima, koji se provode na najmanje jednom serveru:
A TF-bearing microvesicle according to claim 6 or a pharmaceutical composition according to any of claims 7 to 11 for use as a medicament. 
Mikrovezikula koja nosi tkivni faktor kako je definirana u patentnom zahtjevu 9 ili farmaceutski sastav kako je definiran u bilo kojem od patentnih zahtjeva 10 ili 11 za uporabu kao lijek.
determining a proportion of each chromosome of the fetal genome that has been sequenced from the biological sample. 
određivanje udjela svakog kromosoma fetusnog genoma sekvenciranog iz biološkog uzorka.
The lighting module of claim 1, wherein said microchip is an integrated circuit. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da je navedeni mikročip integrirani sklop.
A process according to claim 1, which comprises the steps of: reacting 4-bromo-2,6-difluoroaniline with 3-methoxyphenylboronic acid to obtain 3,5-difluoro-3'-methoxybiphenyl-4-amine, forming and isolating an aminium salt of 3,5-difluoro-3'-methoxybiphenyl-4-amine obtained in step a) by mixing an acid selected from the group consisting of hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, p-toluenesulfonic acid and mixtures thereof with a solution or suspension of 3,5-difluoro-3'-methoxybiphenyl-4-amine in a solvent selected from the group consisting of n-hexane, dichloromethane, ethylene glycol, propylene glycol, n-propyl acetate, isopropyl acetate and mixtures thereof, and 
Postupak prema zahtjevu 1 koji se sastoji od sljedećih koraka: a) reakcije 4-bromo-2,6-difluoroanilina s 3-metoksifenilbornom kiselinom kako bi se dobio 3,5-difluoro-3?- metoksibifenil-4-amin, b) formiranje i izdvajanje aminijeve soli 3,5-difluoro-3'-metoksibifenil-4-amina dobivenog u koraku a) miješanjem kiseline odabrane iz skupine koja se sastoji od klorovodične kiseline, dušične kiseline, fosforne kiseline, sumporne kiseline, p-toluensulfonske kiseline i njihovih smjesa s otopinom ili suspenzijom 3,5-difluoro-3'-metoksibifenil-4-amina u otapalu odabranom iz skupine koja se sastoji od n-heksana, diklorometana, etilen glikola, propilen glikola, n-propil acetata, izopropil acetata i njihovih smjesa, c1) reakcije aminijeve soli 3,5-difluoro-3'-metoksibifenil-4-amina iz koraka b) s 2-kloronikotinskom kiselinom.
The coating composition of claim 7, wherein the aluminum powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between 3.9 to 4.5 micrometers and the 90th percentile of the particle size distribution has a diameter of less than or equal to 9.0 micrometers. 
Suspenzija prema bilo kojem od zahtjeva 1 do 2 pri čemu aluminijev prah ili prah aluminijeve legure ima distribuciju veličine čestica, naznačena time što 50. percentil distribucije veličine čestica ima promjer od između 3,9 do 4,5 um. 1 90. percentil distribucije veličine čestica ima promjer od manje od ili jednak 9,0 um.
a decrease in body fat. 
smanjenjem tjelesne masti.
This data indicates that the active species is rapamycin resulting from the hydrolysis of 42-O-(D-Fructosylcarbonyl)rapamycin over the course of the 3-day culturing, and not non-hydrolysed 42-O-(D-Fructosylcarbonyl)rapamycin. 
Ti podaci ukazuju da je aktivna vrsta rapamicin, koji nastaje hidrolizom 42-0-(D-fruktozilkarbonil)rapamicina tijekom trodnevnog uzgoja u kulturi, a ne ne-hidrolizirani 42-0-(D-fruktozilkarbonil)rapamicin.
The reaction was stirred at 0 °C for four and a half hours then 160mL EtOAc and 100mL water was charged to the flask and the pH of the reaction solution was adjusted to approximately 8 using 3M NaOH. 
Reakcijska smjesa je bila miješana pri O?C četiri i pol sata i tada je 160 mL EtOAc i 100 mL vode bilo stavljeno u tikvicu i pH otopine reakcijske smjese je podešen na približno 8 pomoću 3MNaOH.
solid tumour cancer; or 
Tak čvrstog tumora; ili
Use of a compound according to any one of claims 1 to 47 in the manufacture of a medicament for use in treatment to control or decrease weight gain in an individual. 
Uporaba pripravka u skladu s bilo kojim zahtjevom 1 do 31, 33, 35, 37, 40, 42, 45 i 47, naznačena time, da se koristi u izradi lijeka za uporabu u liječenju kontroliranja ili smanjivanja povećanja težine kod pojedinca.
The composition of claim 1, wherein the composition is lyophilized. A pharmaceutical composition comprising a therapeutically effective amount of the composition of claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da sadrži terapeutski učinkovitu količinu sastava prema bilo kojem od patentnih zahtjeva 1-7 i farmaceutski prihvatljiv nosilac.
Other criteria for selection of the first oligomer assembly are set out below. 
(32) Datum podnošenja prve prijave: 30.05.2007.
provided that the compound is not of the formula: 
uz uvjet da spoj nema formulu: ili njihova farmaceutski prihvatljiva sol.
A receiving device (10), which is installed on the train, and configured so as to acquire the images (5) sent by the transmission means (6) and display them on a screen; 
- prijemni uređaj (10), koji je instaliran na vlaku, te je konfiguriran tako da pribavlja slike (5) poslane pomoću sredstva za prijenos (6) i prikazuje ih na zaslonu;
The use of any one of the preceding items, wherein said CD3 binding domain is a bispecific single chain antibody. 
Glukokortikoid za uporabu iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je navedena CD3 vezna domena bispecifično jednolančano protutijelo.
Disclosed is a combination of lipophilic extracts of Zingiber officinale and Echinacea angustifolia for the treatment of itching, peripheral pain, superficial and deep inflammatory and painful states, pain associated with muscle spasms, herpes pain, and radiodermatitis caused by oncological radiotherapy, with or without fungal or bacterial infections. 
Kombinacija lipofilnih ekstrakata Zingiber officinale i Echinacea angustifolia za upotrebu u liječenju svrbeži, periferne boli, površinskih ili dubokih upala i bolnih stanja, boli povezanih s mišićnim spazmama, boli urokovanih herpesom, radiodermatitisa induciranog onkološkom radioterapijom sa ili bez gljivičnih ili bakterijskih infekcija, edema ili iritativnih stanja kože uključujući one od pretjeranog izlaganja sunčevu svijetlu.
A therapeutic antibody which is an antibody or antigen binding fragment and/or derivative thereof which binds B-amyloid peptide and which comprises the following CDRs: 
PATENTNI ZAHTJEVI Terapijsko protutijelo, naznačeno time što je protutijelo ili njegov antigenski vežući fragment i/ili derivat koji se veže na P-amiloidni peptid i koji sadrži sljedeće CDR-e:
The composition of any one of claims 1 to 10, wherein the type of multiple sclerosis is primary progressive. Use of aminopyridine in the manufacture of a sustained release composition for treating multiple sclerosis, wherein said composition is administered twice daily in a dose of 10 milligrams or less of aminopyridine. 
Primjena aminopiridina u proizvodnji kompozicije za produženo oslobađanje za povećanje brzine hoda pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom dva puta na dan u terapeutskoj dozi od 15 miligrama ili manje aminopiridina.
removing said precipitated phosphate compounds from said first leach solution; 
uklanjanje (225) spomenutih istaloženih fosfatnih spojeva iz spomenute prve otopine za ispiranje;
Method for introducing a substance into a plant (P), in particular a pot plant, the method comprising the following steps: 
Postupak za uvođenje tvari u biljku (P), naročito u lončanicu, te postupak obuhvaća slijedeće korake:
Another aspect of the invention is a valve assembly comprising a housing and a valve, the valve disposed within the housing, and, a radio frequency identification device adapted to communicate with a radio frequency receiver. 
Indeksirani uređaj za ograničavanje sadržaja lijeka (24) prema bilo kojem od zahtjeva 1-5, naznačen time da nadalje sadrži radio frekvencijski identifikacijski uređaj (50) prilagođen za komuniciranje s radio frekvencijskim prijemnikom.
Use according to claim 13, wherein the clinical condition is gastro-oesophageal reflux disease (GERD). 
Dozirni oblik za uporabu prema zahtjevu 11 ili 12, naznačen time, da kliničko stanje je gastro-ezofagealna refluksna bolest (GERD).
This was collected and dried before dissolving in ethyl acetate. 
Isti se sakupi i suši prije otapanja u etilacetatu.
The speed of the rotor was kept at 300 rev/min during the pelletization and at 500 rev/min during drying of the pellets. 
Brzina rotora održavana je na 300 okr/min tijekom granuliranja i na 500 okr/min tijekom sušenja granula.
The method of para 13, wherein the disease is rheumatoid arthritis, multiple sclerosis and psoriasis. 
Spoj za uporabu prema patentnom zahtjevu 6, pri čemu je bolest reumatoidni artritis, multipla skleroza ili psorijaza.
Specifically, Maxisorb™ 96-well immunoplates were coated with synthetic peptide (0.2µg of peptide in a 100µl phosphate buffered saline (PBS) solution and incubated at 4°C overnight). 
Konkretno, multitiracijske pločice MaxisorbT" sa 96 bunarića se obloži sintetskim peptidom (0.2 ug peptida u 100 ul fosfatom puferirane slane otopine (PBS-a) i inkubira pri 4 *C preko noći).
The method according to claim 1, wherein the compound of formula I is administered as a pharmaceutical composition that comprises as an active ingredient a compound of formula I or a pharmaceutically acceptable salt of the compound and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time da kao aktivnu tvar sadrži spoj kao što je definirano u bilo kojem od patentih zahtjeva od 1 do 4 ili odgovarajuću farmaceutski prihvatljivu sol spoja, ili hidrat ili solvat spoja te farmaceutski prihvatljiv nosač.
Lactose monohydrate, microcrystalline cellulose, the active ingredient, the hydroxypropyl methyl cellulose and half of the croscarmellose sodium were screened into a 10 Liter Fielder high-shear blender (any suitable high shear blender could be used) and blended for 5 minutes at 300 rpm with the chopper off. 
Laktoza monohidrat, mikrokristalna celuloza, aktivni sastojak, hidroksipropil metil celuloza i polovica kroskarameloza natrija se prosiju u 10-litrenu Fielder miješalicu s visokim smicanjem (može se upotrijebiti bilo koja prikladna miješalica s visokim smicanjem) i miješaju 5 minuta pri 300 okr/min s isključenim vibratorom.
the VH domain or substantial portion thereof comprises an amino acid sequence as set out in SEQ ID NO:2; or 
VH-domena ili njezin bitni odsječak sadrži aminokiselinsku sekvencu iznesenu u SEQ ID NO:2; ili
preparation of the glass pane by removing all impurities and minor surface defects on the glass side to be coated, polishing and further warming up to a temperature of about 25°C, deposition of a layer of metallic silver (10) 
obrada ploče od stakla uklanjanjem svih nečistoća i sitnih površinskih defekata na onoj strani stakla koja se treba prekriti slojem, poliranje i daljnje zagrijavanje do temperature od oko 25ºC,
The dosage form of claim 5, wherein the active ingredient is an HIV protease inhibitor or a combination of HIV protease inhibitors. 
Doza temeljem bilo kojeg od prethodnih zahtjeva, naznačena time da je aktivni sastojak inhibitor proteaze HIV-a ili kombinacija inhibitora proteaze HIV-a.
The heating system according to claim 1, wherein said heat exchanger is configured to provide a galvanic separation of said primary heating liquid from said secondary heating liquid. 
Sustav za grijanje (100) prema tvrdnji 1, pri čemu je navedeni izmjenjivač topline (130) konfiguriran da omogući galvansko odvajanje (134) navedene primarne tekućine za grijanje iz navedene sekundarne tekućine za grijanje.
s′)—Moving the milling machine to a second traffic lane adjacent to the first one; 
s ́) - pomicanje glodalice (100a-100e) drugom trakom (FSt2) uz prvu;
The apparatus of claim 1, further comprising one or more field concentration points, for concentrating the electromagnetic energy in discrete locations. The apparatus of claim 1, wherein the electromagnetic energy is microwave energy. 
Uređaj (10) prema patentnom zahtjevu 1 ili 2, naznačen time, što dodatno sadrži jednu ili više terenskih točaka koncentracije, za koncentriranje mikrovalne energije u diskretnim lokacijama.
A wind turbine for converting wind energy into electric energy, comprising: 
Vjetroturbina (1) za pretvaranje energije vjetra u električnu energiju, sadrži:
a portion of said container not filled with foodstuffs, with a gas mixture, 
dijela navedenog spremnika koji nije napunjen prehrambenim proizvodima, smjesom plinova,
Identity and purity of r-hIL-18BP fractions were analysed on a RP-HPLC (RP-HPLC Column Supelcosil LC308 Cat No. 
Identitet i čistoća frakcija r-hIL-18BP analizirani su na koloni za RP-HPLC (kolona za RP-HPLC Supelcosil LC308 Cat No.
a solenoid connected to the second end of the fitting. 
solenoid (400) je spojen na drugi kraj priključka (240).
As shown in these figures, the stability of the new formulations was higher than the stability of the conventional formulations. 
HR P20070374 T3 Kao što je prikazano na ovim slikama, stabilnost novih oblika bila je veća od stabilnosti konvencionalnih oblika.
phenyl or substituted phenyl, which is selected from the group consisting of 
fenila ili supstituiranog fenila, koji je odabran od grupe koja se sastoji od [image] [image] [image]
The aqueous pharmaceutical suspension according to claim 3, wherein the sorbic acid or potassium sorbate is, by weight/volume (g/100 mL), 0.10% to 0.22%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sorbinska kiselina ili kalijev sorbat iznosi, težinski/volumno (g/100 ml), otprilike 0,10 % do otprilike 0,22 %,
To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term “about”. 
Da bi se osigurao koncizniji opis, neki od kvantitativnih izraza koji su ovdje dani nisu ograničeni pojmom,,oko".
The resulting salt can then be modified by conventional techniques to give a pharmaceutically acceptable salt of the compound. 
Takva se sol može potom modificirati konvencionalnim postupcima kako bi se dobila farmaceutski prihvatljiva sol spoja.
A compound or a pharmaceutically acceptable salt or N-oxide thereof according to claim 1, which is selected from the group consisting of: 
Spoj prema zahtjevu 1 naznačen time da je odabran iz skupine koju čine:
A vectored vaccine comprising a non-replicating or replication impaired poxvirus vector expressing the translation product of the nucleotide sequence of SEQ ID NO: 4, and additionally including a PK C-terminus tag and a TPA leader sequence, wherein said vectored vaccine is capable of inducing an immune response which persists for at least one year. 
Vektorsko cjepivo koje sadrži poxvirus kao ne-replicirajući vektor, ili vektor s poremećajem replikacije, koji eksprimira produkt translacije nukleotidne sekvence SEQ ID NO: 4, i dodatno sadrži s PK označen C-kraj, TPA vodeću sekvencu, pri čemu to vektorsko cjepivo može inducirati imuni odgovor koji traje najmanje 1 godinu.
A compound of general formula (I) wherein 
PATENTNI ZAHTJEVI Spoj opće formule (D
wherein the antisense oligonucleotide is covalently attached to a cell-penetrating peptide and linker moiety of the formula -G-CPP, wherein G is the linker moiety selected from glycine, cysteine, proline, 6-aminohexanoic acid (Ahx), B-alanine (B), and Ahx-B, and CPP is the cell-penetrating peptide and is selected from SEQ ID NOS: 39-54. The method of claim 10, where at least 5% of the intersubunit linkages are linkage (B). The method of claim 10, where 10% to 50% of the intersubunit linkages are linkage (B). 
pri čemu barem jedna od veza između podjedinica je veza (B), ili pri čemu svaka veza (B) ako postoji ima istu strukturu pri svakom pojavljivanju; i pri čemu je protusmjerni oligonukleotid kovalentno vezan na peptid koji prodire u stanicu i skupinu poveznice, pri čemu je skupina poveznice odabrana iz skupa koji čine glicin, cistein, prolin, 6-aminoheksanoična kiselina (Ahx), B-alanin (B), i Ahx-B, a peptid koji prodire u stanicu je odabran od SEQ ID NOs: 39-54.
The CD37-specific binding molecule of claim 1, consisting of the amino acid sequence set forth in SEQ ID NO:253. 
Molekula koja se specifično veže na CD37, u skladu s patentnim zahtjevom 1, naznačena time što ima aminokiselinski slijed iznijet u SEQ ID NO:253.